Alzheimer Europe

Making dementia a priority:
changing perceptions, practice and policy.

CLINICAL TRIALS WATCH

ACCESSIBLE EASY READ INFORMATION ON:

Gamma tACS STUDY

Alzheimer Europe A.S.B.L. • R.C.S. Luxembourg F2773 • 14, rue Dicks • L-1417 Luxembourg
Tel.: +352-29 79 70 • Fax: +352-29 79 72 • info@alzheimer-europe.org • www.alzheimer-europe.org

Gamma tACS study

1. Study Information	
Name of the study	Non-invasive neurostimulation as a tool for diagnostics and management for neurodegenerative diseases
Study sponsor	Kuopio University Hospital
Diseases	Dementia with Lewy Bodies, Alzheimer's disease, Frontotemporal dementia
Phase	Not applicable – Procedural intervention (brain stimulation)

2. Information about the intervention that will be tested in the study	
Name of the intervention	Gamma tACS (transient alternating current stimulation)
Administration	The intervention will be administered via a brain stimulation on the posterior parietal cortex (this means that electrodes are placed on the scalp over the specific area of the brain named posterior parietal cortex).
Will all participants receive the same intervention?	Participants will be selected at random to either receive one of the following options: • Brain stimulation of gamma tACS over the superior parietal cortex • Brain stimulation of sham over the superior parietal cortex (also called a dummy intervention which is an inactive brain stimulation identical in appearance to the intervention being tested with no active therapeutic effect). Neither the participant nor their doctor will know if the person is receiving the active brain stimulation or not.

3. Information about participating in the study	
What are the researchers trying to find out?	• The purpose of the study is to evaluate whether repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in people with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

How long will the intervention last?	• Brain stimulation once a day during four consecutive days
What your involvement will entail?	• Participants will be asked to complete several tests to assess verbal learning, memory, recognition and orientation. Further information on the procedures, tests and visits can be obtained from the study team.

4. Who can participate in this study?	
Who can participate in the study?	To take part in the study, participants must: • Be 18 years old and older • Have a diagnosis of mild cognitive impairment due to Alzheimer's disease, dementia with Lewy Bodies or frontotemporal dementia. • Be patient of the Kuopio University Hospital Neuro Center.
Who cannot participate in the study?	Exclusion criteria include: • History of seizures (this is uncontrolled electrical disturbances in the brain) • Pregnancy • Metal implants in the head (except dental fillings) • Electronic implants (i.e. pace-maker, implanted medical pump). The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

5. Where and when will the study be conducted?	
European country involved in the trial	• Finland
Estimated start date of recruitment	November 2022

6. Information for your doctor	
Clinicaltrials.gov identifier	NCT05326750
Study contact information	Eino Solje +358 17 713 311 eino.solje@uef.fi
Link to full text	https://clinicaltrials.gov/ct2/show/NCT05326750

- ✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on January 2023.

- ✓ This document has been reviewed by the institution running this trial.